[go: up one dir, main page]

BG105886A - Кристална структура на cpla2 и методи за идентифициране на нейни агонисти и антагонисти - Google Patents

Кристална структура на cpla2 и методи за идентифициране на нейни агонисти и антагонисти

Info

Publication number
BG105886A
BG105886A BG105886A BG10588601A BG105886A BG 105886 A BG105886 A BG 105886A BG 105886 A BG105886 A BG 105886A BG 10588601 A BG10588601 A BG 10588601A BG 105886 A BG105886 A BG 105886A
Authority
BG
Bulgaria
Prior art keywords
methods
crystal structure
identifying
cpla
agonists
Prior art date
Application number
BG105886A
Other languages
English (en)
Inventor
Andrea Dessen
William SOMMERS
Mark Stahl
Jasbir Seehra
Original Assignee
Genetics Institute, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute, Llc filed Critical Genetics Institute, Llc
Publication of BG105886A publication Critical patent/BG105886A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Изобретението се отнася до кристален сPLA2, до кристална структура на cPLA2, получена с такъв материал, както и до модели, базирани на такава кристална структура. Изобретението се отнася също и до методи за идентифициране на инхибитори на сРLA2 активност и мембранно свързване с помощта на такива модели.
BG105886A 1999-02-15 2001-09-10 Кристална структура на cpla2 и методи за идентифициране на нейни агонисти и антагонисти BG105886A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/250,083 US6801860B1 (en) 1999-02-15 1999-02-15 Crystal structure of cPLA2 and methods of identifying agonists and antagonists using same
PCT/US2000/003745 WO2000047763A1 (en) 1999-02-15 2000-02-14 CRYSTAL STRUCTURE OF cPLA2, AND METHODS OF IDENTIFYING AGONISTS AND ANTAGONISTS USING SAME

Publications (1)

Publication Number Publication Date
BG105886A true BG105886A (bg) 2002-05-31

Family

ID=22946256

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105886A BG105886A (bg) 1999-02-15 2001-09-10 Кристална структура на cpla2 и методи за идентифициране на нейни агонисти и антагонисти

Country Status (23)

Country Link
US (1) US6801860B1 (bg)
EP (1) EP1155144A4 (bg)
JP (1) JP2002540766A (bg)
KR (1) KR20010103010A (bg)
CN (1) CN1238520C (bg)
AU (1) AU779488B2 (bg)
BG (1) BG105886A (bg)
BR (1) BR0008231A (bg)
CA (1) CA2362612A1 (bg)
CZ (1) CZ20012933A3 (bg)
EA (1) EA200100899A1 (bg)
EE (1) EE200100426A (bg)
HK (1) HK1040745A1 (bg)
HR (1) HRP20010678A2 (bg)
HU (1) HUP0200554A3 (bg)
IL (1) IL144673A0 (bg)
MX (1) MXPA01008192A (bg)
NO (1) NO20013947L (bg)
NZ (1) NZ514176A (bg)
PL (1) PL351242A1 (bg)
SK (1) SK11782001A3 (bg)
TR (1) TR200102366T2 (bg)
WO (1) WO2000047763A1 (bg)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001286931A1 (en) 2000-08-30 2002-03-13 The Salk Institute For Biological Studies Methods and compositions for determining isomerase enzymatic activity
AU2001290240A1 (en) * 2000-09-19 2002-04-02 Kyowa Hakko Kogyo Co. Ltd. Polypeptide having phospholipase a2 actiivty
ES2252079T3 (es) * 2000-11-07 2006-05-16 I.R.B. Istituto Di Ricerche Biotecnologiche S.R.L. Derivados de glicerofosfoinositol como moduladores de fosfolipasa a2 citosolica.
CA2439182C (en) * 2001-02-22 2009-04-14 Japan Science And Technology Corporation Novel calcium-independent phospholipases a2, genes thereof and promoter of the same
US8206753B2 (en) 2001-06-20 2012-06-26 Metaproteomics, Llc Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
US7270835B2 (en) * 2001-06-20 2007-09-18 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US7901713B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llc Inhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived from hops
US7901714B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llp Treatment modalities for autoimmune diseases
US7718198B2 (en) * 2001-06-20 2010-05-18 Metaproteomics, Llc Treatment modalities for autoimmune diseases
US20040115290A1 (en) 2001-06-20 2004-06-17 Tripp Matthew L. Modulation of inflammation by hops fractions and derivatives
US7815944B2 (en) * 2001-06-20 2010-10-19 Metaproteomics, Llc Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment of prevention of gastric toxicity
US8168234B2 (en) 2001-06-20 2012-05-01 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US8142819B2 (en) 2002-10-21 2012-03-27 Metaproteomics, Llc Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response
US7205151B2 (en) * 2001-06-20 2007-04-17 Metaproteomics, Llc Complex mixtures exhibiting selective inhibition of cyclooxygenase-2
US8158160B2 (en) 2001-11-13 2012-04-17 Eric Hauser Kuhrts Anti-inflammatory cyclooxygenase inhibitors
US8486457B2 (en) * 2002-10-21 2013-07-16 Metaproteomics, Llc. Compositions that treat or inhibit pathological conditions associated with inflammatory response
US7811610B2 (en) * 2003-05-22 2010-10-12 Metaproteomics, Llc Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity
US20050192356A1 (en) * 2004-02-27 2005-09-01 Babish John G. Synergistic anti-inflammatory pharmaceutical compositions and methods of use
US7914831B2 (en) 2004-02-27 2011-03-29 Metaproteomics, Llc Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
WO2006053249A2 (en) * 2004-11-13 2006-05-18 Metaproteomics, Llc Compositions exhibiting inhibition of cyclooxygenase-2
US7931904B2 (en) 2005-02-15 2011-04-26 Dana Farber Cancer Institute, Inc. Modulation of MUC1 activity
EP2248532A1 (en) * 2005-08-09 2010-11-10 Metaproteomics, LLP Protein kinase modulation by hops and acacia products cross-reference to related applications
WO2007024940A2 (en) 2005-08-22 2007-03-01 Dana-Farber Cancer Institute, Inc. Mitochondrial localization of muc1
AU2006321727A1 (en) * 2005-12-09 2007-06-14 Metaproteomics, Llc Protein kinase modulation by hops and Acacia products
US20080031893A1 (en) * 2006-06-20 2008-02-07 Metaproteomics, Llc Acacia based protein kinase modulation cancer treatment
WO2008097840A2 (en) 2007-02-02 2008-08-14 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of muc1 by hsf1 and stat3
US7871784B2 (en) 2007-02-02 2011-01-18 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins
WO2008101121A2 (en) 2007-02-14 2008-08-21 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to promoter regulation by muc1 and klf proteins
WO2008115783A1 (en) * 2007-03-19 2008-09-25 Metaproteomics, Llc Methods and compositions for promoting bone and joint health
US8241674B2 (en) * 2007-05-11 2012-08-14 Metaproteomics, Llc Methods and compositions for heavy metal detoxification
CA2708613A1 (en) * 2007-12-10 2009-06-18 Metaproteomics, Llc Substituted 1,3-cyclopentadione multi-target protein kinase modulators of cancer, angiogenesis and the inflammatory pathways associated therewith
EP2268600A4 (en) * 2008-04-02 2012-03-21 Metaproteomics Llc SUBSTITUTED 1,3-CYCLOPENTADION-ENHANCED ENDOTHELIAL IGNITION AND ENDOTHELIAL MONOCYTE INTERACTIONS
US8524669B2 (en) 2008-10-17 2013-09-03 Dana-Farber Cancer Institute, Inc. MUC-1 cytoplasmic domain peptides as inhibitors of cancer
FI20105629A0 (fi) * 2010-06-03 2010-06-03 Estaja Oy Menetelmä lipidiaktivoituvien entsyymien peptidi-inhibiittoreiden valmistamiseksi ja menetelmällä valmistettuja peptidejä
CA2905986A1 (en) 2013-03-15 2014-09-25 Bayer Healthcare Llc Gla domains as therapeutic agents
KR20200050961A (ko) 2017-09-05 2020-05-12 글래디에이터 바이오사이언시스 인코포레이티드 줄기세포로의 페이로드의 전달
CN117187211B (zh) * 2023-08-04 2025-04-01 华南理工大学 一种磷脂酶c晶体及磷脂酶c突变体的制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622832A (en) 1990-02-28 1997-04-22 Genetics Institute, Inc. Arachidonic acid releasing phospholipase A2 enzyme and methods of use
CA2061738A1 (en) * 1991-03-01 1992-09-02 Ruth M. Kramer Antibodies reactive with human cytosolic phospholipase a2
IL101507A0 (en) 1991-04-17 1992-12-30 Lilly Co Eli Compounds,vectors and methods for expressing human,cytosolic phospholipase a2
US5221410A (en) 1991-10-09 1993-06-22 Schering Corporation Crystal forming device
US5466595A (en) 1994-07-27 1995-11-14 Genetics Institute, Inc. Calcium independent cytosolic phospholipase A2/B enzymes

Also Published As

Publication number Publication date
KR20010103010A (ko) 2001-11-17
WO2000047763A1 (en) 2000-08-17
BR0008231A (pt) 2001-10-30
CN1348502A (zh) 2002-05-08
AU2993700A (en) 2000-08-29
HK1040745A1 (zh) 2002-06-21
EA200100899A1 (ru) 2002-04-25
PL351242A1 (en) 2003-04-07
AU779488B2 (en) 2005-01-27
CA2362612A1 (en) 2000-08-17
HUP0200554A2 (en) 2002-06-29
SK11782001A3 (sk) 2002-03-05
NZ514176A (en) 2004-09-24
MXPA01008192A (es) 2002-10-23
EE200100426A (et) 2002-12-16
EP1155144A1 (en) 2001-11-21
US6801860B1 (en) 2004-10-05
TR200102366T2 (tr) 2002-02-21
NO20013947L (no) 2001-10-10
HRP20010678A2 (en) 2003-08-31
HUP0200554A3 (en) 2006-06-28
JP2002540766A (ja) 2002-12-03
IL144673A0 (en) 2002-05-23
CZ20012933A3 (cs) 2002-02-13
EP1155144A4 (en) 2002-08-28
CN1238520C (zh) 2006-01-25
NO20013947D0 (no) 2001-08-14

Similar Documents

Publication Publication Date Title
BG105886A (bg) Кристална структура на cpla2 и методи за идентифициране на нейни агонисти и антагонисти
ATE413386T1 (de) Ppar-gamma modulatoren
DE69841510D1 (de) Unterstützungsmethode zur betrachtung von aufgezeichneten programmen
EP1127054A4 (en) INHIBITORS OF IMPDH ENZYME
AU2003265859A8 (en) Assays and compositions for identifying agents that modulate the activity of deubiquitinating agents
IL141957A0 (en) 5ht1 receptor agonists and metoclopramide for the treatment of migraine
NO20012095D0 (no) Sammensetninger og fremgangsmåter for fremstilling av dispersjoner og fremgangsmåter for anvendelse av dispersjonene
EP1122342A4 (en) PROCESS FOR REMOVING DEFECTS FROM CRYSTAL MATERIAL AND CRYSTAL MATERIAL
ZA200103184B (en) Open cast mining apparatus and apparatus for testing the recoverability cutting of critical material.
MY133625A (en) Peptide deformylase inhibitors
HUP0101640A3 (en) Certain thoil inhibitors of endothelin-converting enzyme
AU4842399A (en) An in-line method for determining the residue content of an isocyanate and apparatus useful therefor
AU9627498A (en) Method and apparatus for measuring the degree of polarisation of polarised gas
AU3180800A (en) Method and apparatus for the analysis of material composition
IL124199A (en) Apparatus for cleaving crystals
AU2001258568A1 (en) Ligands specific for an isoform of the prion protein
AU6947500A (en) Methods for identifying modulators of transcriptional activator protein interactions
AU2002258437A1 (en) Peptide deformylase inhibitors
AU2001281957A1 (en) Support plate and method for the carrying out of functional tests
IL163899A0 (en) Peptide deformylase inhibitors
AP2002002493A0 (en) Sodium-hydrogen exchanger type 1 inhibitor crystals.
AU2002322035A1 (en) Peptide deformylase inhibitors
NZ336908A (en) Substrates for human cytomegalovirus protease
AU2002255635A1 (en) Peptide deformylase inhibitors
ES1039752U (es) Almohada perfeccionada.